Efficacy of antitumor therapy schemes with carboplatin in an experimental model of lung carcinoma and drug-resistant tuberculosis
Abstract
Introduction. Up to 20% of tuberculosis patients suffer from malignant neoplasms. In this case, the combination of both diseases in the lung is a particular problem. More than 60% of patients cannot complete combination therapy due to drug-resistant MBT. The aim of the study was a preclinical study of the efficacy and safety of combination regimens of antitumor therapy using carboplatin and antituberculosis therapy for drug-resistant tuberculosis. The study was supported by grant No.22-15-00470 from the Russian Science Foundation (https://rscf.ru/project/22-15-00470/) Material and methods. The study was conducted on 40 C57BL/6 mice aged two months with pre-modeled combined pathology of lung carcinoma and tuberculosis. Depending on the therapy, 4 groups were formed: I – control without treatment (n = 10), II – antitumor (carboplatin + paclitaxel) + antituberculosis therapy (n = 10), III – antitumor (carboplatin + pemetrexed) + antituberculosis therapy (n = 10), IV – antitumor (carboplatin + gemcitabine) + antituberculosis therapy (n = 10). The antituberculosis therapy regimen included moxifloxacin, linezolid, bedaquiline and perchlozone. The antitumor effect (tumor growth index, tumor growth inhibition), antituberculosis effect (CFU per lung weight), toxicity (biometric parameters of internal organs), and survival were assessed. Statistical processing was performed using non-parametric statistics methods. Results. The lowest average body weight was recorded in the control…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.